Abstract 4367443: Who Can Safely Stop Anticoagulation Following Left Ventricular Thrombus Resolution
Abstract
Background: Whether oral anticoagulation (OAC) can be discontinued after the resolution of left ventricular thrombus (LVT) remains controversial, particularly in patients without risk factors such as left ventricular aneurysms. This study aimed to identify patients who may safely discontinue OAC. Methods: We conducted a retrospective cohort study of patients with LVT resolution who completed their anticoagulation course and excluded patients with left ventricular (LV) aneurysm. Clinical and echocardiographic factors were compared between patients who experienced LVT recurrence (n = 22) and those without recurrence during follow-up (n = 94). Results: The cohort had a mean age of 64.5 ± 15.0 years, and half (50%) were male. Most had an ischemic cardiomyopathy (64.6%). LVT recurred in 19% (22/116) of patients following initial resolution. Patients with recurrence were older (mean age 71.3 ± 11.9 vs. 63.4 ± 15.7 years, p = 0.03) and were more likely to have prior ischemic stroke and arterial thromboembolism (18.2% vs. 4.3%, p = 0.02 for both). At the time of thrombus resolution, LVEF was significantly lower among patients who had recurrence (33.4 ± 13.6% vs. 42.5 ± 15.5%, p = 0.012). Stroke, systemic embolism, and mortality rates were similar regardless of recurrence status. Recurrence risk by presence or absence of stroke and LEVF >50% on the LVT resolution echocardiogram is shown in Figure 1. Notably, no recurrences were observed among patients with both LVEF > 50% and no history of stroke (0/32), which was statistically significant compared to each other category. Conclusion: Among patients without left ventricular aneurysm who discontinued oral anticoagulation after LVT resolution, those with preserved LVEF (>50%) and no prior history of stroke had a very low risk of recurrence, with no events observed in this subgroup. These findings suggest that some patients may safely discontinue anticoagulation after LVT resolution.
Article Details
Authors (12)
Hossam Elbenawi
Mayo Clinic, Rochester, Minnesota, United States
Kirsten Lipps
Mayo Clinic, Rochester, Minnesota, United States
Samuel Heller jr.
Second Faculty of Medicine, Charles University, Prague, Prague, Czechia
Robert McBane
MAYO CLINIC, Rochester, Minnesota, United States
Waldemar Wysokinski
Mayo Clinic, Rochester, Minnesota, United States
Ana Casanegra
Mayo Clinic, Rochester, Minnesota, United States
Stanislav Henkin
Thom Rooke
Mayo Clinic, Rochester, Minnesota, United States
Paul Wennberg
Mayo Clinic, Rochester, Minnesota, United States
David Liedl
Mayo Clinic, Rochester, Minnesota, United States
Raymond C Shields
Mayo Clinic, Rochester, Minnesota, United States
Damon Houghton
Mayo Clinic, Rochester, Minnesota, United States